AZ ups emerging markets bet with $200M plant in China

AstraZeneca ($AZN) has announced a $200 million investment to build a pharma manufacturing plant in China Medical City, Jiangsu Province. The company says the financial commitment is its largest ever in a single manufacturing facility.

The plant is expected to produce both intravenous and oral solid medicines.

The new plant "will complement our efforts to meet the medical needs of Chinese patients with medicines that are locally produced," AZ China president Mark Mallon says in the statement.

The new plant, for which AZ expects construction to be complete by late 2013, will also complement an existing manufacturing and supply site in Wuxi New District, Jiangsu Province.

- see the AZ release
- here's the story

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.